Patterns of SARS-CoV-2-specific humoral and cellular immune
response in actively treated patients with solid cancer
following prime BNT162b2 COVID-19 vaccination: results from
phase IV CoVigi trial

ENPřihlásit se Přihlásit se (EduID)

Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients ...

Přehled o publikaci

J 2025

Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial

LORDICK OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dominika OKRUHLICOVÁ; Jiří NEVRLKA et. al.

Základní údaje

Originální název

Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial

Autoři

Vydání

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, LONDON, SAGE PUBLICATIONS LTD, 2025, 1758-8340

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Lékařská fakulta – Masarykova univerzita – Repozitář

DOI

https://doi.org/10.1177/17588359251316224

UT WoS

001489582200001

EID Scopus

2-s2.0-105005423791

Klíčová slova anglicky

COVID-19 vaccination; immune response; SARS-CoV-2 antibodies; SARS-CoV-2-specific T-cell response; solid cancer

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód Repo. LX22NPO5102, projekt VaV. 101059788, interní kód Repo. CZECRIN IV, velká výzkumná infrastruktura.

Změněno: 15. 10. 2025 00:50, RNDr. Daniel Jakubík

Anotace

V originále

amp; iuml;ve patients with cancer developed anti-S antibodies after the first vaccine dose, rising to 92% after the second dose. By 6 months, all BNT162b2-vaccinated patients with solid cancer developed antibody response. Patients treated with CT showed impaired both humoral and cellular immune response to BNT162b2 vaccination. Antibody levels in SARS-CoV-2-recovered patients were comparable to healthy controls. T-cell response peaked after the second dose of BNT162b2 and was not significantly impaired in solid cancer patients except those treated with CT.Conclusion: Immune response to BNT162b2 COVID-19 mRNA vaccine is substantially shaped by pre-vaccination COVID-19 infection. All patients with solid cancer on active anticancer therapy exhibited seroconversion after COVID-19 vaccination, although the extent of both humoral and cell immune response was substantially hampered in those treated by CT.Trial registration: EudraCT No. 2021-000566-14 (registration date February 17, 2021).

Přiložené soubory

https://is.muni.cz/publication/2499760/Patterns_of_SARS-CoV-2-specific_humoral_and_cellular_immune_response_in_actively_treated_patients_with_solid_cancer_following_prime_BNT162b2_COVID-19_vaccination_results_from_phase_IV_CoVigi_trial.pdf

Citovat

LORDICK OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dominika OKRUHLICOVÁ; Jiří NEVRLKA; Kateřina ČERNÁ PILÁTOVÁ; Kristina GREPLOVA; Zdenka CERMAKOVA; Dalibor VALÍK; Igor KISS; Marketa PALACOVA; Alexandr POPRACH; Hana LEJDAROVA; Sarka SELVEKEROVA; Martina VANECKOVA a Lenka ZDRAŽILOVÁ DUBSKÁ. Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. LONDON: SAGE PUBLICATIONS LTD, 2025, roč. 17, May 2025, s. 1-15. ISSN 1758-8340. Dostupné z: https://doi.org/10.1177/17588359251316224.

@article{74371,
   author = {Lordick Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Okruhlicová, Dominika and Nevrlka, Jiří and Černá Pilátová, Kateřina and Greplova, Kristina and Cermakova, Zdenka and Valík, Dalibor and Kiss, Igor and Palacova, Marketa and Poprach, Alexandr and Lejdarova, Hana and Selvekerova, Sarka and Vaneckova, Martina and Zdražilová Dubská, Lenka},
   article_location = {LONDON},
   article_number = {May 2025},
   doi = {https://doi.org/10.1177/17588359251316224},
   keywords = {COVID-19 vaccination; immune response; SARS-CoV-2 antibodies; SARS-CoV-2-specific T-cell response; solid cancer},
   language = {eng},
   issn = {1758-8340},
   journal = {THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY},
   title = {Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial},
   url = {https://journals.sagepub.com/doi/10.1177/17588359251316224},
   volume = {17},
   year = {2025}
}

TY  - JOUR
ID  - 74371
AU  - Lordick Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Okruhlicová, Dominika - Nevrlka, Jiří - Černá Pilátová, Kateřina - Greplova, Kristina - Cermakova, Zdenka - Valík, Dalibor - Kiss, Igor - Palacova, Marketa - Poprach, Alexandr - Lejdarova, Hana - Selvekerova, Sarka - Vaneckova, Martina - Zdražilová Dubská, Lenka
PY  - 2025
TI  - Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial
JF  - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
VL  - 17
IS  - May 2025
SP  - 1-15
EP  - 1-15
PB  - SAGE PUBLICATIONS LTD
SN  - 1758-8340
KW  - COVID-19 vaccination
KW  - immune response
KW  - SARS-CoV-2 antibodies
KW  - SARS-CoV-2-specific T-cell response
KW  - solid cancer
UR  - https://journals.sagepub.com/doi/10.1177/17588359251316224
N2  - amp; iuml;ve patients with cancer developed anti-S antibodies after the first vaccine dose, rising to 92% after the second dose. By 6 months, all BNT162b2-vaccinated patients with solid cancer developed antibody response. Patients treated with CT showed impaired both humoral and cellular immune response to BNT162b2 vaccination. Antibody levels in SARS-CoV-2-recovered patients were comparable to healthy controls. T-cell response peaked after the second dose of BNT162b2 and was not significantly impaired in solid cancer patients except those treated with CT.Conclusion: Immune response to BNT162b2 COVID-19 mRNA vaccine is substantially shaped by pre-vaccination COVID-19 infection. All patients with solid cancer on active anticancer therapy exhibited seroconversion after COVID-19 vaccination, although the extent of both humoral and cell immune response was substantially hampered in those treated by CT.Trial registration: EudraCT No. 2021-000566-14 (registration date February 17, 2021).
ER  -

LORDICK OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dominika OKRUHLICOVÁ; Jiří NEVRLKA; Kateřina ČERNÁ PILÁTOVÁ; Kristina GREPLOVA; Zdenka CERMAKOVA; Dalibor VALÍK; Igor KISS; Marketa PALACOVA; Alexandr POPRACH; Hana LEJDAROVA; Sarka SELVEKEROVA; Martina VANECKOVA a Lenka ZDRAŽILOVÁ DUBSKÁ. Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial. \textit{THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY}. LONDON: SAGE PUBLICATIONS LTD, 2025, roč.~17, May 2025, s.~1-15. ISSN~1758-8340. Dostupné z: https://doi.org/10.1177/17588359251316224.